Compare DSGN & SCZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSGN | SCZM |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Canada |
| Employees | N/A | 455 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.6M | 744.7M |
| IPO Year | 2021 | N/A |
| Metric | DSGN | SCZM |
|---|---|---|
| Price | $10.74 | $8.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $15.25 | $12.00 |
| AVG Volume (30 Days) | ★ 950.1K | 564.4K |
| Earning Date | 04-28-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $79.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.33 | $5.88 |
| 52 Week High | $17.25 | $17.65 |
| Indicator | DSGN | SCZM |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 53.75 |
| Support Level | $9.78 | $7.17 |
| Resistance Level | $11.18 | $8.77 |
| Average True Range (ATR) | 0.60 | 0.57 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 44.09 | 82.22 |
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.